AbbVie is now in a 5-year relationship with Johns Hopkins and Northwestern University. The goal? Advancing oncology R&D. The pharmaceutical giant will work with each university independently, providing funding for preclinical research and access to AbbVie’s existing research. Of course, in the spirit of reciprocation, AbbVie can exclusively claim any new discoveries as its own. Therapeutic areas of research will include breast, lung, prostate, and colorectal cancers, among others. This is not the first time AbbVie has tapped the power of academic institutions. They entered a multi-million dollar oncology research collaboration with University of Chicago last April. Arrangements like these have the potential to be a win-win-win for pharma, academia and patients alike. After all, sharing is caring.